5PSQ-076 Patient-reported outcomes in multiple sclerosis

• Published in: European journal of hospital pharmacy. Science and practice Vol. 25; no. Suppl 1; pp. A199 - A200
• Main Authors: Sacristan, A Garcia, Sánchez, P López, Sesmero, JM Martínez, Ambel, H Quiros, Barahona, A Dominguez, Suarez, S Gonzalez, Gomez, P Moya
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.03.2018; BMJ Group
• Subjects: Drug stores; Monoclonal antibodies; Multiple sclerosis; Patient satisfaction; Pharmacists; Questionnaires; Section 5: Patient safety and quality assurance
• ISSN: 2047-9956; 2047-9964
• DOI: 10.1136/ejhpharm-2018-eahpconf.430

BackgroundMultiple sclerosis (MS) is a chronic neurological disease that carries important personal, social and economic consequences for patients and their environment. Hospital pharmacists are responsible for effective and safe use of drugs, but also to improve Quality of Life (QoL) and therefore, it is important to evaluate QoL factors related, such as patient satisfaction and activation (or having the knowledge, skills and confidence to manage one’s health, to be related to health-related outcomes).PurposeThe aim is to measure MS patients’ satisfaction with their medication and the patient activation level.Material and methodsObservational, prospective and analytical study, carried out in two hospitals from June 2017 to September 2017. Two validated questionnaires (Treatment Satisfaction Questionnaire for Medication version 1.7 – TQSM1.7: effectiveness score 0–21 points, adverse events score 0–21 points, convenience score 0–21 points, global satisfaction 0–17 points – and Patient Activation Measure questionnaire – PAM: 0–100 points) were completed by MS patients attending the Outpatient Pharmacy Department. We collected the patients’ electronic medical record: sex, age, date of diagnosis, drug treatment, MS type (relapsing remitting MS-RRMS or secondary progressive MS-SPMS) and Expanded Disability Status Scale (EDSS). Statistical analysis was performed using SPSS®21.ResultsOne hundred and three patients (35.9% males, 64.1% females) answered the questionnaires, mean age 42.67 years (23–65 years). Treatment: 17.5% interferon-B-1a im, 16.5% interferon-B-1a sc, 4.9% peginterferon-B-1a, 9.7% interferon-B-1b, 13.6% glatiramer acetate, 8.7% dimetilfumarate, 13.6% fingolimod, 3.9% teriflunomide, 7.8% natalizumab, 3.9% fampridine. Median treatment duration was 46.94 months (3–216) and 53.4% were MS treatment-naïve. MS types 93.2% RRMS and median EDSS=2.2.TQSM1.7: average value of effectiveness was 14.3, 13.95 in adverse effects (60 patients answered, the rest did not report adverse effects), 14.26 in convenience and 13.3 in global satisfaction. PAM: 19.4% were classified in level 1, 26.2% in level 2, 41.7% in level 3% and 11.7% in level 4.ConclusionThere is a low patient activation level (45.6% are in levels 1 and 2), however global satisfaction is high (13.3). Effectiveness and convenience of treatment are well valued. As pharmacists it is necessary to identify which groups of patients are the least activated and make a special emphasis on increasing their involvement with the disease to improve health outcomes.References and/or AcknowledgementsNo conflict of interest